Accretion Pharmaceuticals Limited ACCPLshare price and chart
Accretion Pharmaceuticals closed at ₹204.00 on 19 November 2026, up 1.22% on the day. The 52-week range is ₹62.00 to ₹220.00.
Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.
Loading prices…
Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.Test a strategy on ACCPL
Real prices, every charge counted. Pick one or write your own.Accretion Pharmaceuticals, based in Ahmedabad and started in 2012, is a contract development and manufacturing organisation making tablets, capsules, oral liquids and ointments in antibiotic, antifungal, antiallergic, cold, antacid, vitamin and cardiac therapies at a WHO-cGMP certified facility, for markets in India and over 30 countries.
Pharmaceuticals & Biotechnology
Tablets, capsules, oral liquids, ointments
Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.
EOD 19 NovThe share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.
Returns and valuationWhat the market pays for this company and how well the business uses its money.
Books to 30 Sept 2026Against its sectorWhere this company ranks among similar companies on each measure.
Pharmaceuticals · 141 peers · mediansWhat it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.
Price only, before dividendsShareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.
Who owns itEach line is that holder's share of all shares over the last 4 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.
The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.
Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.
Last 6 monthsKey ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.
Against its sectorPeers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.
Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.
Where the cash wentIn FY26 cash rose by ₹4 Cr, after ₹9 Cr spent on plant and equipment.
Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.
| Measure | FY25 | FY26 |
|---|---|---|
| ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders. | 38.1% | 28.9% |
| Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | 0.92x | 0.23x |
Each row against this company's own usual level: green better, red worse, grey close to it.
Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.
Pharmaceuticals| Company | What the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality. | How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit. | The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business. | How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money. | How much operating profit the company made on all the money in the business, whether it came from owners or lenders. | Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings. | Of every ₹100 of sales, how much is left as profit after all costs, interest and tax. | How much sales grew in the latest quarter against the same quarter a year earlier. | The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share. |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | 4.56 L cr | 41.6x | 5.1x | 14.7% | 19.1% | 0.03 | 17.8% | +11.9% | 0.84% |
| DIVISLAB Divi's Laboratories Limited | 2.97 L cr | 88.2x | 16.5x | 16.2% | 21.5% | 0.00 | 27.6% | +35.4% | 0.27% |
| TORNTPHARM Torrent Pharmaceuticals Limited | 1.75 L cr | 77.9x | 9.6x | 17.0% | 15.2% | 0.76 | 12.1% | +50.8% | 0.82% |
| LAURUSLABS Laurus Labs Limited | 1.25 L cr | 92.9x | 20.6x | 17.7% | 17.9% | 0.40 | 17.0% | +33.4% | 0.10% |
| ZYDUSLIFE Zydus Lifesciences Limited | 1.20 L cr | 28.9x | 4.3x | 18.3% | 19.9% | 0.44 | 14.1% | +29.2% | 0.08% |
| DRREDDY Dr. Reddy's Laboratories Limited | 1.17 L cr | 41.7x | 3.0x | 11.5% | 13.9% | 0.15 | 8.3% | -1.5% | 0.57% |
| CIPLA Cipla Limited | 1.15 L cr | 39.5x | 3.2x | 11.7% | 16.0% | 0.01 | 10.1% | -2.4% | 0.92% |
| MANKIND Mankind Pharma Limited | 1.09 L cr | 48.4x | 6.2x | 12.4% | 12.9% | 0.30 | 14.7% | +17.3% | 0.00% |
| AUROPHARMA Aurobindo Pharma Limited | 1.04 L cr | 26.2x | 2.6x | 9.9% | 12.8% | 0.21 | 10.8% | +23.9% | 0.39% |
| LUPIN Lupin Limited | 91,403 cr | 17.6x | 3.8x | 26.9% | 28.8% | 0.23 | 17.0% | +11.1% | 0.90% |
| GLENMARK Glenmark Pharmaceuticals Limited | 73,618 cr | 50.7x | 6.6x | 14.1% | 20.4% | 0.08 | 9.2% | -31.3% | 0.10% |
| ALKEM Alkem Laboratories Limited | 61,516 cr | 29.8x | 4.1x | 17.6% | 20.6% | 0.12 | 13.4% | +13.8% | 1.03% |
| BIOCON Biocon Limited | 59,264 cr | 216.5x | 1.7x | 1.1% | 3.0% | 0.41 | 1.9% | +2.2% | 0.14% |
| ABBOTINDIA Abbott India Limited | 54,600 cr | 33.0x | - | - | - | - | 23.0% | +11.0% | 2.55% |
| GLAND Gland Pharma Limited | 54,336 cr | 43.9x | 5.1x | 10.5% | 15.0% | 0.02 | 17.5% | +23.3% | 0.61% |
| IPCALAB IPCA Laboratories Limited | 47,189 cr | 33.6x | 5.4x | 13.2% | 16.6% | 0.06 | 14.2% | +13.8% | 0.32% |
| GLAXO GlaxoSmithKline Pharmaceuticals Limited | 45,967 cr | 40.6x | 24.4x | 48.9% | 66.5% | 0.00 | 27.6% | +20.8% | 2.10% |
| EMCURE Emcure Pharmaceuticals Limited | 44,481 cr | 40.7x | 8.3x | 19.6% | 24.8% | 0.27 | 10.7% | +24.3% | 0.15% |
| AJANTPHARM Ajanta Pharma Limited | 40,865 cr | 32.4x | 8.4x | 25.4% | 32.7% | 0.02 | 20.3% | +32.5% | 0.98% |
| SAILIFE Sai Life Sciences Limited | 37,985 cr | 100.5x | 14.1x | 15.1% | 20.9% | 0.17 | 15.9% | +22.5% | 0.00% |
| WOCKPHARMA Wockhardt Limited | 35,537 cr | 86.7x | 6.9x | 4.0% | 6.5% | 0.39 | 10.8% | +23.9% | 0.00% |
| ACUTAAS Acutaas Chemicals Limited | 32,561 cr | 74.1x | 17.5x | 23.5% | 31.7% | 0.00 | 27.5% | +42.7% | 0.06% |
| PPLPHARMA Piramal Pharma Limited | 31,906 cr | - | 3.9x | -4.0% | 0.8% | 0.69 | -2.1% | +28.1% | 0.00% |
| RUBICON Rubicon Research Limited | 28,510 cr | 87.3x | 20.1x | 19.1% | 23.4% | 0.28 | 15.5% | +39.9% | 0.09% |
| NEULANDLAB Neuland Laboratories Limited | 27,074 cr | 59.8x | 13.3x | 21.4% | 27.5% | 0.17 | 19.6% | -12.6% | 0.16% |
| APLLTD Alembic Pharmaceuticals Limited | 20,631 cr | 24.4x | 3.5x | 12.4% | 11.7% | 0.25 | 9.9% | +36.3% | 1.14% |
| GRANULES Granules India Limited | 19,853 cr | 27.7x | 3.0x | 13.5% | 15.7% | 0.09 | 12.1% | +20.3% | 0.22% |
| ERIS Eris Lifesciences Limited | 18,418 cr | 25.8x | 4.4x | 18.1% | 13.9% | 0.58 | 21.6% | +12.6% | 0.54% |
| ONESOURCE Onesource Specialty Pharma Limited | 18,381 cr | - | 3.1x | -1.3% | 0.4% | 0.25 | -0.1% | +37.4% | 0.00% |
| ALIVUS Alivus Life Sciences Limited | 17,801 cr | 26.6x | 4.9x | 18.4% | 24.6% | 0.00 | 24.9% | +16.0% | 0.34% |
| SHILPAMED Shilpa Medicare Limited | 17,616 cr | 52.7x | 6.4x | 9.8% | 11.4% | 0.24 | 18.1% | +43.0% | 0.07% |
| PFIZER Pfizer Limited | 17,614 cr | 20.5x | 4.0x | 17.2% | 23.4% | 0.00 | 32.4% | +13.2% | 1.95% |
| COHANCE Cohance Lifesciences Limited | 17,578 cr | 510.5x | 4.5x | 5.1% | 8.0% | 0.06 | -0.3% | -14.2% | 0.00% |
| NATCOPHARM Natco Pharma Limited | 16,124 cr | 17.8x | 1.6x | 16.9% | 17.1% | 0.11 | 26.9% | -29.0% | 0.70% |
| CAPLIPOINT Caplin Point Laboratories Limited | 15,845 cr | 23.0x | 4.1x | 19.9% | 24.7% | 0.00 | 29.4% | +17.9% | 0.38% |
| ASTRAZEN AstraZeneca Pharma India Limited | 15,283 cr | 86.0x | 17.4x | 22.8% | 31.2% | 0.00 | 6.8% | +30.4% | 0.59% |
| JUBLPHARMA Jubilant Pharmova Limited | 14,865 cr | 56.2x | 2.1x | 6.0% | 8.7% | 0.54 | 2.9% | +20.5% | 0.54% |
| CORONA CORONA Remedies Limited | 13,680 cr | 66.1x | 17.0x | 24.8% | 27.8% | 0.12 | 13.3% | +22.2% | 0.45% |
| MARKSANS Marksans Pharma Limited | 13,556 cr | 24.2x | 4.1x | 25.4% | 35.1% | 0.01 | 16.7% | +30.5% | 0.30% |
| ACCPL Accretion Pharmaceuticals Limited | 227 cr | 17.3x | 3.6x | - | 28.9% | 0.27 | 13.0% | +25.9% | 0.00% |
Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.
Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.
Month by month| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -23.3 | +5.3 | -10.5 | +71.0 | +12.9 | +32.9 | +4.2 | +21.8 | +3.4 | -11.2 | +7.3 | · | +132.2% 11m |
| 2025 | · | · | · | · | · | +7.9 | -11.1 | -2.7 | -2.5 | +1.5 | +68.7 | -13.1 | +35.4% 7m |
Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.
Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.
| Date | Party | Side | Quantity | Price | Value |
|---|---|---|---|---|---|
| 2025-11-18 | KHUSHBOO NAHAR · bulk | BUY | 97,200 | ₹76.79 | ₹0.75 Cr |
| 2025-05-21 | GRETEX SHARE BROKING LIMITED · bulk | SELL | 1,40,400 | ₹82.95 | ₹1.16 Cr |
- Board outcomeOutcome of Board Meeting2 Nov 2026
Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
- Board outcomeOutcome of Board Meeting31 Oct 2026
Accretion Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the half year ended September 30, 2026.
- Board outcomeOutcome of Board Meeting8 May 2026
Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
- Press releasePress Release17 Nov 2025
Accretion Pharmaceuticals Limited has informed the Exchange regarding a press release dated November 17, 2025, titled "Media Release for the half year ended on 30th September, 2025".
- Board outcomeOutcome of Board Meeting14 Nov 2025
Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
- Board outcomeOutcome of Board Meeting11 Jun 2025
Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
- Board outcomeOutcome of Board Meeting10 Jun 2025
Accretion Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2025.
The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.
Read enough? Test ACCPL. “Buy ACCPL when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.
Run it free